#1 Clinical Trials Search in Europe

Human Papillomavirus Type 11 L1 Protein

This article summarizes several clinical trials investigating the use of Human Papillomavirus Type 11 L1 Protein as part of the 9-valent HPV vaccine (9vHPV or Gardasil 9) for various medical conditions. The trials aim to evaluate the vaccine’s safety, immunogenicity, and efficacy in different patient populations and dosing regimens. The studies cover a range of applications, from preventing HPV infections and related diseases to treating existing HPV-related conditions.

Table of Contents

What is the Human Papillomavirus Type 11 L1 Protein Vaccine?

The Human Papillomavirus Type 11 L1 Protein vaccine is one component of a 9-valent HPV vaccine called Gardasil 9. This vaccine contains proteins from nine different types of human papillomavirus (HPV), including HPV type 11.[1] The vaccine is made using recombinant DNA technology and yeast cells to produce virus-like particles that mimic the HPV virus but do not cause infection.

How Does It Work?

The vaccine works by stimulating the body’s immune system to produce antibodies against HPV type 11 and other included HPV types. These antibodies help protect against future HPV infections. The vaccine contains L1 proteins, which are the major capsid proteins that form the outer shell of the HPV virus. When injected, these L1 proteins self-assemble into virus-like particles that trigger an immune response without causing infection.[1]

What Does It Treat and Prevent?

The HPV type 11 component, along with the other HPV types in the vaccine, helps prevent several conditions:

  • Persistent anogenital HPV infections
  • Cervical, vulvar, vaginal, and anal cancers caused by HPV
  • Genital warts (specifically related to HPV types 6 and 11)
  • Precancerous or dysplastic lesions caused by the included HPV types

HPV type 11 is particularly associated with genital warts and some low-grade cervical lesions.[1]

Dosing and Administration

The vaccine is typically administered as a series of intramuscular injections. The standard dosing schedule includes:

  • 3-dose regimen: Injections given at 0, 2, and 6 months
  • 2-dose regimen: For younger individuals (usually ages 9-14), injections may be given 6-12 months apart

Each dose contains 0.5 ml of the vaccine suspension.[1]

Effectiveness

Clinical trials have shown the 9-valent HPV vaccine to be highly effective in preventing infections and diseases caused by the included HPV types. For HPV type 11 specifically, the vaccine has demonstrated high efficacy in preventing genital warts. Studies have shown seroconversion rates (development of antibodies) of over 99% for HPV type 11 one month after completing the vaccination series.[1]

Safety and Side Effects

The vaccine has been shown to be generally safe and well-tolerated. Common side effects may include:

  • Pain, swelling, or redness at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness

Serious allergic reactions are rare but possible. As with any vaccine, patients should be monitored for any signs of severe allergic reaction after administration.[1]

Who Can Receive the Vaccine?

The vaccine is approved for use in both males and females. Specific recommendations may vary by country, but generally:

  • It is routinely recommended for adolescents aged 11-12, but can be given starting at age 9
  • Catch-up vaccination is recommended for females through age 26 and males through age 21 if not adequately vaccinated previously
  • It may be given to adults up to age 45, based on individual risk factors and discussion with a healthcare provider

The vaccine is not recommended for pregnant women or individuals with severe allergies to vaccine components.[1]

Ongoing Research

Several clinical trials are currently investigating various aspects of the 9-valent HPV vaccine, including:

  • Extended dosing intervals in younger age groups
  • Effectiveness in immunocompromised populations
  • Use in preventing oral HPV infections in adult males
  • Potential benefits in women treated for high-grade cervical lesions
  • Efficacy in treating difficult-to-treat palmar or plantar warts

These studies aim to further optimize vaccine use and explore potential new applications.[2]

Trial Focus Key Objectives Patient Population Dosing Regimen
Extended dosing intervals Compare immunogenicity of 2-dose vs 3-dose regimens 9-14 year olds and 16-26 year old women 2 doses with 12-60 month intervals vs 3 doses
Immunocompromised patients Evaluate immunogenicity in various immunocompromised groups Children and adolescents aged 9-18 years 3 doses at 0, 2, and 6 months
Oral HPV prevention Assess efficacy in preventing oral persistent HPV infection Adult males aged 20-45 years 3 doses at 0, 2, and 6 months
Post-transplant vaccination Compare early vs late vaccination after stem cell transplant Allogeneic stem cell transplant recipients ≥18 years 3 doses starting at 9 or 15 months post-transplant
Vulvar HSIL treatment Evaluate efficacy in preventing recurrence after treatment Women with vulvar HSIL 3 doses over 6 months
Cervical lesions in older women Assess HPV clearance after treatment for high-grade lesions Women over 45 years 3 doses over 6 months
Palmar/plantar warts Evaluate efficacy in treating difficult-to-treat warts Patients ≥15 years with treatment-resistant warts 3 doses over 6 months

FAQ

  • What is the 9-valent HPV vaccine? The 9-valent HPV vaccine (9vHPV or Gardasil 9) is a vaccine that protects against nine types of human papillomavirus (HPV), including types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It contains virus-like particles of the L1 protein from each of these HPV types.
  • What age groups are being studied in these clinical trials? The clinical trials cover various age groups, including children and adolescents aged 9-14 years, young adults aged 16-26 years, adult males aged 20-45 years, and women over 45 years old. Some studies also focus on specific populations such as immunocompromised patients.
  • What are the main objectives of these clinical trials? The main objectives vary across trials but generally include evaluating the vaccine's safety, immunogenicity (ability to produce an immune response), and efficacy in preventing HPV infections or treating HPV-related conditions. Some trials also compare different dosing schedules or study the vaccine's effectiveness in specific patient populations.
  • How is the vaccine administered in these trials? The vaccine is typically administered as an intramuscular injection. Most trials use a 3-dose regimen, but some studies are investigating 2-dose regimens with extended intervals between doses.
  • What are some of the conditions being studied in relation to the HPV vaccine? The clinical trials are studying the vaccine's effectiveness in preventing or treating various conditions, including persistent HPV infections, cervical intraepithelial lesions, vulvar high-grade squamous intraepithelial lesions (vHSIL), and difficult-to-treat palmar or plantar warts.

Ongoing Clinical Trials on Human Papillomavirus Type 11 L1 Protein

  • Study on HPV Vaccine Timing for Patients After Stem Cell Transplantation Using Gardasil 9

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Human Papillomavirus (HPV): A group of viruses that can cause various types of cancer and genital warts. There are many different types of HPV, some of which are targeted by the 9-valent HPV vaccine.
  • 9vHPV vaccine: A vaccine that protects against nine types of HPV (6, 11, 16, 18, 31, 33, 45, 52, and 58). It is also known as Gardasil 9.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent, indicating an immune response to vaccination or infection.
  • Geometric Mean Titer (GMT): A measure of the average antibody level in a group of individuals, used to assess the immune response to a vaccine.
  • Competitive Luminex Immunoassay (cLIA): A laboratory test used to measure antibody levels in response to vaccination.
  • High-grade Squamous Intraepithelial Lesion (HSIL): Abnormal, precancerous changes in the cells of the cervix or vulva that are detected through screening tests.
  • Allogeneic Stem Cell Transplantation (AlloSCT): A procedure where stem cells from a donor are transplanted into a patient to treat certain blood and immune system disorders.
  • Graft-versus-Host Disease (GvHD): A complication that can occur after stem cell or bone marrow transplantation, where the donor's immune cells attack the recipient's tissues.
  • Virus-Like Particles (VLPs): Structures that mimic viruses but do not contain viral genetic material, used in vaccines to stimulate an immune response.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-timing-for-patients-after-stem-cell-transplantation-using-gardasil-9/